MISC--: understanding mechanisms cell function drug action major endeavor pharmaceutical industry
MISC--: drug effects governed intrinsic properties drug specific signaling transduction network host
MISC--: here we describe unbiased phosphoproteomic based approach identify drug effects monitoring drug induced topology alterations
MISC--: our proposed method drug effects investigated under diverse stimulations signaling network
OWNX--: starting generic pathway made logical gates we build cell type specific map constraining fit key phopshoprotein signals under experimental conditions
MISC--: fitting performed via integer linear program formulation solution standard ilp solvers procedure drastically outperforms previous fitting schemes
MISC--: then knowing cell s topology we monitor same key phosphoprotein signals under presence drug we re optimize specific map reveal drug induced topology alterations
OWNX--: prove our case we make topology hepatocytic cell line hepg we evaluate effects drugs selective inhibitors epidermal growth factor receptor non selective drug
OWNX--: we confirm effects easily predictable drugs main target but we also uncover unanticipated effects due either drug promiscuity cell s specific topology
MISC--: interesting finding selective egfr inhibitor gefitinib inhibits signaling downstream interleukin alpha pathway effect cannot extracted binding affinity based approaches
OWNX--: our method represents unbiased approach identify drug effects small medium size pathways scalable larger topologies any type signaling interventions
OWNX--: method reveal drug effects pathways cornerstone identifying mechanisms drug s efficacy
MISC--: target based drug discovery predominant focus pharmaceutical industry
MISC--: primary objective selectively target protein within diseased cells order ameliorate undesired phenotype e g unrestrained cell proliferation inflammatory cytokine release
OWNX--: ideally other pathways within diseased cells well similar phenotypes other cell types should remain unaffected therapeutic approach
MISC--: however despite plethora new potential targets emerged sequencing human genome rather few proven effective clinic citation
MISC--: major limitation inability understand mechanisms drug actions either due complex signaling transduction networks cells due complicated profile drug potency selectivity
MISC--: finding drug s targets traditionally based high throughput vitro assays using recombinant enzymes protein fragments citation
MISC--: main goal characterize drug s biochemical activity depict them drug interaction maps citation
MISC--: most cases once target known vivo effect signaling pathway validated measuring drug s efficiency inhibit activity downstream protein
MISC--: however beyond measurement little know how rest signaling network affected
MISC--: addition vivo drug effects hardly calculated vitro assays several reasons most kinase inhibitors promiscuous citation there discrepancy between vivo vitro binding affinities drugs citation there additional discrepancy between vivo binding affinities vivo inhibitor activity phosphorylation downstream signals
MISC--: address drug effects more physiological conditions novel genomic proteomic tools recently been developed citation
CONT--: genomic arena large scale mrna analysis enhanced computational approaches drug target deconvolution been developed
MISC--: despite holistic advantages genomic approaches offer proteomic based discovery step closer function cell
OWNX--: towards this goal affinity chromatography offers viable strategy vivo target identification
OWNX--: this approach utilizes solid support linked bait enrich cellular binding proteins identified mass spectrometry citation
MISC--: however experiments usually require large amounts starting protein biased toward more abundant proteins result several hits due nonspecific interactions citation citation
MISC--: order circumvent non specific interaction problem another bait based strategy uses quantitative ms dirty inhibitors baits immobilize kinome citation citation
OWNX--: while this approach significantly reduces non specific interaction problem also limits target searching space those kinases highest affinity bait
MISC--: more recently quantitative ms based proteomics using silac technology citation extends search space all targets do not bind covalently drug
OWNX--: however incorporation silac s isotopes requires population doublings thus excludes application primary cells limited replication capabilities
MISC--: taken together all techniques listed above best case scenario list affinities all targets drug but no information provided whether this binding affinity capable inhibiting transmission signal downstream protein how those preferential bindings collectively affect signaling network cell
OWNX--: here we describe significantly different approach identify drug effects where drugs evaluated alterations they cause signaling pathways
OWNX--: instead identifying binding partners we monitor pathway alterations following key phosphorylation events under several treatments cytokines
MISC--: workflow presented figure
MISC--: experimental front using bead based multiplexed assays citation we measure key phosphorylation events under more than different conditions generated combinatorial treatment stimuli selective inhibitors
MISC--: based signaling response priori set possible reactions we create cell type specific pathway using efficient optimization formulation known integer linear programming
CONT--: this approach builds upon boolean optimization approach proposed citation
MISC--: ilp solved using standard commercial software packages guaranteed global optimality
OWNX--: evaluate drug effects we subject cells same stimuli presence drugs we tract alterations same key phosphorylation events
OWNX--: then we reapply ilp formulation without priori assumption drug target we monitor changes pathway topology without drug presence
OWNX--: demonstrate our approach we construct generic map optimize fit phosphoproteomic data transformed hepatocytic cell lines hepg
MISC--: then we identify effects four drugs dual egfr erbb inhibitor lapatinib citation two potent egfr kinase inhibitors erlotinib citation gefitinib citation dirty raf kinase inhibitor sorafenib citation
OWNX--: when our method applied those drugs we find their main target effect we also uncover several unknown but equally active off target effects
OWNX--: case gefitinib we find surprising inhibition cjun il pathway
OWNX--: contrast previously developed techniques our method based actual effect phosphorylation events carefully spread into signaling network
AIMX--: theoretically applied any type intracellular perturbations atp based allosteric kinase inhibitors rnai shrna etc computational front our ilp based approach performs faster more efficient than current algorithms pathway optimization citation identify main drug effects well unknown off target effects areas pathways constrained between activated receptors measured phosphorylated proteins
MISC--: our fast unbiased characterization modes drug actions shed light into potential mechanisms drug s efficacy toxicity
